Bacterial Biofilm Eradication Agents: A Current Review.
Verderosa AD, Totsika M, Fairfull-Smith KE. · 2019
Read Bacterial Biofilm Eradication Agents: A Current Review. by Verderosa AD, Totsika M, Fairfull-Smith KE. (2019) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc6893625.txt.
Introduction
Verderosa and co-authors review agents that eradicate bacterial biofilms, in Frontiers in Chemistry. Most bacteria can settle on surfaces and build biofilms, layered communities wrapped in self-made slime. Biofilms shrug off antibiotics that kill free-floating cells. They drive stubborn, returning infections by organisms such as Pseudomonas aeruginosa and Staphylococcus aureus.
Most drug work aims to stop biofilms forming or to break them apart. Neither directly kills an established film. This review covers the rarer class that does: eradication agents meant as stand-alone treatment. Halogenated phenazines and quinolines lead the field, with strong action against staph species and low cell toxicity. None, the authors note, has yet been tested in a living body.
Catalog record
| CREATOR | Verderosa AD, Totsika M, Fairfull-Smith KE. |
|---|---|
| YEAR | 2019 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 88 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Bacterial Biofilm Eradication Agents: A Current Review By Anthony D. Verderosa, Makrina Totsika, Kathryn E. Fairfull-Smith Published in: Frontiers in Chemistry DOI: 10.3389/fchem.2019.00824 ABSTRACT Most free-living bacteria can attach to surfaces and aggregate to grow into multicellular communities encased in extracellular polymeric substances called biofilms. Biofilms are recalcitrant to antibiotic therapy and a major cause of persistent and recurrent infections by clinically important pathogens worldwide (e.g., Pseudomonas aeruginosa, Escherichia coli, and Staphylococcus aureus). Currently, most biofilm remediation strategies involve the development of biofilm-inhibition agents, aimed at preventing the early stages of biofilm formation, or biofilm-dispersal agents, aimed at disrupting the biofilm cell community. While both strategies offer some clinical promise, neither represents a direct treatment and eradication strategy for established biofilms. Consequently, the discovery and development of biofilm eradication agents as comprehensive, stand-alone biofilm treatment options has become a fundamental area of research. Here we review our current understanding of biofilm antibiotic tolerance mechanisms and provide an overview of biofilm remediation strategies, focusing primarily on the most promising biofilm eradication agents and approaches. Many of these offer exciting prospects for the future of biofilm therapeutics for a large number of infections that are currently refractory to conventional antibiotics. INTRODUCTION Biofilm formation is a significant virulence mechanism in the pathogenesis of many medically important bacterial pathogens, such as Pseudomonas aeruginosa (Gellatly and Hancock, 2013), Staphylococcus aureus (Gordon and Lowy, 2008), and Escherichia coli (Beloin et al., 2008). The number of diseases being attributed or associated with biofilm infections is large, with some common examples including vaginitis (Machado et al., 2016), colitis (von Rosenvinge et al., 2013), conjunctivitis (Behlau and Gilmore, 2008), gingivitis (Vieira Colombo et al., 2016), urethritis (Delcaru et al., 2016), and otitis (Post, 2001). In fact, it is estimated that ~80% of all microbial infections in humans are a direct result of biofilms (Davies, 2003). One biofilm-related infection of particular medical concern is P. aeruginosa biofilms in the lungs of cystic fibrosis patients. This opportunistic pathogen has been known to cause acute and chronic lung infections that can result in significant morbidity and mortality (Wagner and Iglewski, 2008). A second area of considerable concern is that of chronic wound infections. Highly persistent biofilm-related wound infections, which commonly involve the pathogens P. aeruginosa and S. aureus (Omar et al., 2017), are suggested to be responsible for over 80% of the 100,000 limb amputations carried out on diabetic patients in each year (James et al., 2008). An additional area of importance when considering biofilm-related infection is implanted medical devices. Microbial adhesion resulting in biofilm formation on implanted medical devices is a common occurrence and can lead to serious illness and death (Habash and Reid, 1999). These implanted medical devices, which can include intravascular catheters, urinary catheters, pacemakers, heart valves, stents, and orthopedic implants, are commonly used to saves lives but can present a significant health risk when colonized by bacterial biofilms (Francolini and Donelli, 2010). Most antimicrobial treatments available are generally developed and evaluated against microorganisms in the planktonic (free-living) mode of life. Consequently, these treatments are often ineffective against pathogenic biofilms (Costerton et al., 1987; Lebeaux et al., 2014), which can be up to one thousand times more tolerant to antimicrobial treatments (Stewart and William Costerton, 2001; Luppens et al., 2002; Davies, 2003). The phenomenon of biofilm recalcitrance makes them extremely difficult to treat and eradicate effectively. Thus, new strategies for the prevention, dispersal and treatment of bacterial biofilms are urgently required. This review presents an overview of bacterial biofilm development and the current methods used to prevent, disperse, and treat bacterial biofilms, with a particular focus on the development of novel biofilm eradication strategies. BIOFILM FORMATION Biofilms are complex three-dimensional communities of microorganisms adhering to a surface and encased in a protective exopolymeric substance. Biofilm formation progresses over five main stages (Figure 1). In stage one, individual planktonic cells migrate and adhere to a surface. Providing the correct conditions are present, these adherent cells then initiate biofilm production on the surface and become encased in small quantities of exopolymeric material. In stage two, adherent cells exude an extracellular polymeric substance (EPS) and become irreversibly attached to the surface, which results in cell aggregation and matrix formation. In stage three, the biofilm begins to mature by developing microcolonies and water channel architecture, while also becoming significantly more layered. In stage four, the fully mature biofilm reaches its maximum cell density and is now considered a three-dimensional community. In stage five, the mature biofilm releases microcolonies of cells from the main community, which are free to migrate to new surfaces spreading the infection to other locations (Stoodley et al., 2002; Schachter, 2003). [Figure: A model showing the typical stage-wise development of a bacterial biofilm accompanied by transmitted light microscopy images showing these different stages for a P. aeruginosa biofilm. Republished with permission of Annual Reviews, Inc. (Stoodley et al., 2002); permission conveyed through Copyright Clearance Center, Inc.] THE EXTRACELLULAR POLYMERIC SUBSTANCE (EPS) The extracellular matrix encasing the cells in a biofilm, also referred to as the EPS, is composed of a complex mixture of proteins, lipids, nucleic acids (extracellular-DNA), and polysaccharides (Annous et al., 2009). These constituents not only assist in securing the biofilm to the surface, but also trap nutrients, provide structural support, and shield against host immune responses and antimicrobial treatments (Flemming et al., 2007). In addition to the above functions, the EPS is also responsible for holding the community of biofilm cells in close proximity, thereby enabling cell-to-cell communication (quorum sensing), and facilitating the exchange of genetic material through horizontal gene transfer (Hausner and Wuertz, 1999). CELL-TO-CELL COMMUNICATION (QUORUM SENSING) Biofilms are known to control their population density through a cell-to-cell signaling mechanism known as quorum sensing (Schachter, 2003). Cell-to-cell communication is a complex regulatory process which prevents biofilm cell density from reaching an unsustainable level (Nadell et al., 2008). Quorum sensing is reliant on signaling molecules known as autoinducers (Figure 2). These autoinducers are constantly being produced by the bacterial cells, and thus, as cell density increases, so does the level of autoinducers (Figure 3). At a specific cell density, a critical threshold concentration of autoinducers is reached, which is known as the quorum level (Annous et al., 2009). During this time, autoinducer receptor binding leads to the repression or activation of several target genes. This modulation of the quorum sensing process allows bacteria to display a unified response that benefits the entire bacterial community by maintaining the optimal biofilm size and co-ordinating virulence phenotypes (Nadell et al., 2008; Annous et al., 2009; Dickschat, 2010). This unified response allows the biofilm to behave more like a multicellular organism, which enables the bacterial community to adapt to changing environmental conditions. The benefit of quorum sensing is not limited to controlling population density. In fact, quorum sensing has also been shown to aid the spread of beneficial mutations throughout the biofilm colony, enhance access to nutrients, and contribute to antibiotic tolerance (Hannan et al., 2010). [Figure: Chemical structure of two predominant types of small molecule autoinducers involved in quorum sensing.] [Figure: Quorum sensing illustration. During planktonic cell growth (blue ovals), the relative amount of autoinducers (red triangles) is proportionally low. As cells enter a densely populated mode of growth